Silexion Therapeutics Corp. (SLXN) surged 52.40 percent to $1.08, adding $0.37 during Wednesday's trading, after announcing a strategic collaboration with Catalent to support development and manufacturing of its siRNA candidate SIL204 for KRAS-driven cancers.
Shares opened at $0.7589 and have traded between $0.7589 and $1.29 today, compared to the previous close of $0.7156. Volume has soared to 63.65 million shares, far surpassing the average of 13.62 million.
SLXN is now trading well above its 52-week low of $0.2070, though still far from its high of $13.5580.
The partnership focuses on systemic and intratumoral delivery formulations, reinforcing Silexion's dual-route strategy and building on promising preclinical results.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.